Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
5/27/24 Nippon Shinyaku (4516) Viltepso for Duchenne Muscular Dystrophy (DMD) Subscribers Only Subscribers Only Subscribers Only
5/24/24 Novo Nordisk (NVO) Awiqli for Diabetes Mellitus, Type I Subscribers Only Subscribers Only Subscribers Only
5/24/24 Dizal Pharmaceutical (688192) Sunvozertinib for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
5/24/24 Kelun Pharmaceutical (002422) Sacituzumab Tirumotecan for Triple-Negative Breast Cancer (TNBC) Subscribers Only Subscribers Only Subscribers Only
5/23/24 Arcus (RCUS) Etrumadenant for Colorectal Cancer (CRC) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
03/19/24 Subscribers Only Subscribers Only Company - Analyst/R&D Update
04/09/24 Subscribers Only Subscribers Only Company - Analyst/R&D Update
04/15/24 Subscribers Only Subscribers Only Partnership - Acquisition Completion
04/15/24 Subscribers Only Subscribers Only Partnership - Acquisition Completion
04/18/24 Subscribers Only Subscribers Only Company - Analyst/R&D Update